Mylan N.V. Sees Signs of Improvement in the 4th Quarter
Weak North American sales continued to plague the drugmaker in the fourth quarter, but 2018 looks to be a much better year.
http://ift.tt/2F5xOoX
Subscribe to:
Post Comments
(
Atom
)
Post a Comment